Statistical Inference for Heterogeneous Treatment Effect with Right-censored Data from Synthesizing Randomized Clinical Trials and Real-world Data

Guangcai Mao, Shu Yang, Xiaofei Wang

Introduction

In the era of precision medicine, the focus of clinical research has shifted from determining if a treatment works on average to understanding how it works for specific individuals. This is the study of Heterogeneous Treatment Effects (HTE). While Randomized Clinical Trials (RCTs) remain the gold standard for establishing causality due to their controlled nature, they are often limited by small sample sizes, high costs, and restrictive eligibility criteria that may not reflect the broader patient population.

Conversely, Real-World Data (RWD)—derived from electronic health records, insurance claims, and registries—offers massive sample sizes and high diversity. However, RWD is frequently plagued by biases, including unmeasured confounding, differing censoring patterns, and outcome heterogeneity. This paper proposes a novel statistical framework to synthesize RCT and RWD, leveraging the strengths of both to provide more accurate and efficient HTE estimates for survival data.

The Challenge: Bias and Censoring

Estimating HTE in survival analysis is particularly challenging because the data is often "right-censored," meaning the event of interest (e.g., death or disease progression) has not occurred for all subjects by the end of the study. The authors focus on the Conditional Restricted Mean Survival Time (CRMST), which measures the average life expectancy of a patient up to a specific time horizon, given their baseline characteristics.

To integrate RWD without introducing systematic errors, the researchers address three primary sources of bias:

  1. Unmeasured Confounders: Factors influencing both treatment assignment and survival that are not captured in the RWD.
  2. Censoring Bias: Differences in how patients drop out or are followed up between trial and real-world settings.
  3. Outcome Heterogeneity: Differences in baseline risks or treatment responses between the trial population and the general population.

Methodology: The Omnibus Bias Function

The core innovation of this research is the introduction of an omnibus bias function, denoted as $\lambda(X)$. Rather than attempting to model every source of bias individually—which is often impossible with limited data—the authors define a single, flexible function that captures the total discrepancy between the RCT and the RWD.

Penalized Sieve Estimation

To estimate both the HTE and the bias function without relying on rigid, potentially incorrect linear assumptions, the authors employ a penalized sieve method. This approach approximates complex, non-linear functions using a combination of simpler basis functions (such as B-splines). To prevent the model from overfitting to noise in the data, "roughness penalties" are applied, ensuring the resulting estimates are smooth and generalizable.

Theoretical Robustness

The framework is grounded in Reproducing Kernel Hilbert Space (RKHS) theory. The authors prove that their integrative estimator is "double robust," meaning it remains consistent even if parts of the statistical model (like the censoring mechanism) are slightly misspecified. Furthermore, they demonstrate that the estimator converges at an optimal rate and follows a normal distribution, which allows clinicians to construct reliable confidence intervals for treatment recommendations.

Empirical Validation: Lung Cancer Case Study

The methodology was tested through extensive simulations and a high-stakes application involving early-stage non-small-cell lung cancer (NSCLC). The study integrated data from two primary sources:

  • CALGB 140503 (RCT): A Phase III trial of 697 patients comparing lobectomy (removing a full lung lobe) to limited resection (removing a smaller section).
  • National Cancer Database (NCDB) (RWD): A massive registry of 17,995 patients used as supplementary evidence.

Key Findings

The integrative approach provided significantly more granular insights than the RCT data could provide in isolation:

  • Efficiency Gains: The proposed method reduced the standard error of treatment effect estimates by up to 52% in certain patient subgroups compared to using trial data alone.
  • Subgroup Identification: While the original RCT suggested that limited resection was generally "non-inferior" to lobectomy, the new method identified specific patient profiles—specifically younger patients with larger tumors—where lobectomy provided a statistically significant survival benefit.
  • Increased Confidence: The visualizations of the treatment effects showed much larger regions of statistical significance (represented as "blue regions" in the study's analysis), providing doctors with a clearer mandate for tailoring surgical choices to individual patient risks.

Conclusion and Future Directions

By explicitly modeling the bias inherent in real-world evidence, this framework allows researchers to "borrow strength" from large-scale data without compromising the causal integrity of randomized trials. The result is a more powerful tool for precision medicine that can identify which patients benefit most from specific interventions.

While the method is highly effective, the authors note certain limitations. The sieve methods can face the "curse of dimensionality" if too many patient traits are included simultaneously, and the model currently assumes a static, one-time treatment. Future research may extend this framework to handle time-varying treatments and even higher-dimensional data, further refining our ability to deliver the right treatment to the right patient at the right time.

Summary updated

Abstract

The heterogeneous treatment effect plays a crucial role in precision medicine.There is evidence that real-world data, even subject to biases, can be employed as supplementary evidence for randomized clinical trials to improve the statistical efficiency of the heterogeneous treatment effect estimation. In this paper, for survival data with right censoring, we consider estimating the heterogeneous treatment effect, defined as the difference of the treatment-specific conditional restricted mean survival times given covariates, by synthesizing evidence from randomized clinical trials and the real-world data with possible biases. We define an omnibus bias function to characterize the effect of biases caused by unmeasured confounders, censoring, and outcome heterogeneity, and further, identify it by combining the trial and real-world data. We propose a penalized sieve method to estimate the heterogeneous treatment effect and the bias function. We further study the theoretical properties of the proposed integrative estimators based on the theory of reproducing kernel Hilbert space and empirical process. The proposed methodology outperforms the approach solely based on the trial data through simulation studies and an integrative analysis of the data from a randomized trial and a real-world registry on early-stage non-small-cell lung cancer.
BibTeX
@inproceedings{mao2025statistical,
  author = {Guangcai Mao and Shu Yang and Xiaofei Wang},
  title = {{Statistical Inference for Heterogeneous Treatment Effect with Right-censored Data from Synthesizing Randomized Clinical Trials and Real-world Data}},
  booktitle = {Biometrics},
  year = {2025},
  doi = {10.1093/biomtc/ujaf131},
}
Figure